GV 143253
Alternative Names: GV 143253ALatest Information Update: 01 Aug 2023
At a glance
- Originator GlaxoSmithKline
- Class Antibacterials; Lactams
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Methicillin-resistant Staphylococcus aureus infections
Most Recent Events
- 04 Mar 2008 Discontinued - Preclinical for Meticillin-resistant Staphylococcus aureus infections in Italy (Parenteral)
- 28 Feb 2003 Pharmacokinetics, pharmacodynamics and antimicrobial activity data from a preclinical trial in Methicillin-resistant Staphylococcus aureus infections released by GlaxoSmithKline
- 16 Apr 1998 Preclinical development for Methicillin-resistant Staphylococcus aureus infections in Italy (Parenteral)